Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enlonstobart with Chemoradiotherapy for Locally Advanced Cervical Cancer
NCT06981858Phase 2Not yet recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- May 2025
- Primary completion
- Feb 2029
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of PBI-1308 in Cervical Cancer (CC), sponsored by Chongqing University Cancer Hospital. Primary endpoint: 1-year Progression-Free Survival rate. Planned start May 2025; status: not yet recruiting.
02
Drugs
PBI-1308
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06981858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06981858.